Pharmacodynamic-Pharmacokinetic Integration as a Guide to Medicinal Chemistry

被引:24
作者
Gabrielsson, Johan [1 ,5 ]
Fjellstrom, Ola [2 ]
Ulander, Johan [2 ]
Rowley, Michael [3 ]
Van der Graaf, Piet H. [4 ]
机构
[1] AstraZeneca R&D, Discovery DMPK, S-43183 Molndal, Sweden
[2] AstraZeneca R&D, Lead Generat, S-43183 Molndal, Sweden
[3] AstraZeneca R&D, Med Chem, S-43183 Molndal, Sweden
[4] Pfizer Ltd, Sandwich Res Unit, Dept Pharmacokinet Dynam & Metab PDM & Global Pha, Sandwich CT13 9NJ, Kent, England
[5] AstraZeneca R&D, BAC, S-43183 Molndal, Sweden
关键词
Mechanism-based PKPD modelling; potency; efficacy; lipophilicity; structure-activity relationship; turnover models; effect compartment models; occupancy binding models; PLASMA-PROTEIN BINDING; PHARMACOLOGY; RATS; MODEL; TIME;
D O I
10.2174/156802611794480864
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A primary objective of pharmacokinetic-pharmacodynamic (PKPD) reasoning is to identify key in vivo drug and system properties, enabling prediction of the magnitude and time course of drug responses under physiological and pathological conditions in animals and man. Since the pharmacological response generated by a drug is highly dependent on the actual system used to study its action, knowledge about its potency and efficacy at a given concentration or dose is insufficient to obtain a proper understanding of its pharmacodynamic profile. Hence, the output of PKPD activities extends beyond the provision of quantitative measures (models) of results, to the design of future protocols. Furthermore, because PKPD integrates DMPK (e. g. clearance) and pharmacology (e. g. potency), it provides an anchor point for compound selection, and, as such, should be viewed as an important weapon in medicinal chemistry. Here we outline key PK concepts relevant to PD, and then consider real-life experiments to illustrate the importance to the medicinal chemist of data obtained by PKPD. Useful assumptions and potential pitfalls are described, providing a holistic view of the plethora of determinants behind in vitro-in vivo correlations. By condensing complexity to simplicity, there are not only consequences for experimental design, and for the ranking and design of compounds, but it is also possible to make important predictions such as the impact of changes in drug potency and kinetics. In short, by using quantitative methods to tease apart pharmacodynamic complexities such as temporal differences and changes in plasma protein binding, it is possible to target the changes necessary for improving a compound's profile.
引用
收藏
页码:404 / 418
页数:15
相关论文
共 22 条
[11]   Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations [J].
Gabrielsson, Johan ;
Dolgos, Hugues ;
Gillberg, Per-Goran ;
Bredberg, Ulf ;
Benthem, Bert ;
Duker, Goran .
DRUG DISCOVERY TODAY, 2009, 14 (7-8) :358-372
[12]   Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following β-funaltrexamine-induced μ-opioid receptor "knockdown" in vivo [J].
Garrido, M ;
Gubbens-Stibbe, J ;
Tukker, E ;
Cox, E ;
von Frijtag, J ;
Künzel, D ;
IJzerman, A ;
Danhof, M ;
van der Graaf, PH .
PHARMACEUTICAL RESEARCH, 2000, 17 (06) :653-659
[13]   Quantifying Biological Activity in Chemical Terms: A Pharmacology Primer To Describe Drug Effect [J].
Kenakin, Terry .
ACS CHEMICAL BIOLOGY, 2009, 4 (04) :249-260
[14]   Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent [J].
Langdon, Grant ;
Davis, John D. ;
McFadyen, Lynn M. ;
Dewhurst, Mark ;
Brunton, Neil S. ;
Rawal, Jaiessh K. ;
Van der Graaf, Piet H. ;
Benson, Neil .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (04) :336-345
[15]   Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis [J].
Lepist, EI ;
Jusko, WJ .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2004, 27 (04) :211-218
[16]   Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans [J].
Mager, Donald E. ;
Woo, Sukyung ;
Jusko, William J. .
DRUG METABOLISM AND PHARMACOKINETICS, 2009, 24 (01) :16-24
[17]   Impact of plasma-protein binding on receptor occupancy: An analytical description [J].
Peletier, Lambertus A. ;
Benson, Neil ;
van der Graaf, Piet H. .
JOURNAL OF THEORETICAL BIOLOGY, 2009, 256 (02) :253-262
[18]   Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling [J].
Ploeger, Bart A. ;
van der Graaf, Piet H. ;
Danhof, Meindert .
DRUG METABOLISM AND PHARMACOKINETICS, 2009, 24 (01) :3-15
[19]  
Van der Graaf PH, 1999, J PHARMACOL EXP THER, V290, P702
[20]   Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development [J].
Van der Graaf, Piet H. ;
Gabrielsson, Johan .
FUTURE MEDICINAL CHEMISTRY, 2009, 1 (08) :1371-1374